SKYLIGHT 1 and 2

Pivotal phase 3, double-blind, placebo-controlled clinical trials lasting 12 weeks (with an extension to 52 weeks in total), which assessed the efficacy and safety of fezolinetant 45 mg and 30 mg against placebo in women aged 40 to 65 with moderate to severe menopausal hot flushes.

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.